Jiangsu Atom Bioscience & Pharmaceutical Co. Ltd. (Atom Bioscience) 


 Atom Bioscience was founded in 2012. It has mainly focused on the new drug discovery and development on treatment of metabolic disease and cancers. The executive team is primarily from the US and has extensive experience in the pharmaceutical industry. 

Atom Bioscience develops several pipelines. Among them, a novel compound ABP-671 has completed the phase 1 clinical trials in the US, and the phase 2 trials are under way. ABP-671 may  be the potent drug for treatment of gout and other hyperuricemia related diseases worldwide. 

Atom Bioscience also dedicates to development of novel drugs to treat NASH, gastric and colon cancers, etc. The novel compounds ABP-6016 and ABP-431 are currently under pre-clinical development for NASH and gastric cancer, respectively. Both will enter clinical trials in the US or China in 2020.

Atom Bioscience has completed over $42 million (USD) financing at Round Angel, A,A+ and B. Investors are KaiTai Capital, YouChoose Capital, Ch-gemstone Capital, etc.  Round B financing targeting $30 million (USD) has completed at the beginning of 2020.